The Sound of Evolution
Panitumumab
Mechanism of action:
Panitumumab is an anti-EGFR IgG2 monoclonal antibody. Panitumumab binds with high affinity to the extracellular ligand-binding domain of the epidermal growth factor receptor, preventing ligands such as EGF and TGF-alpha from binding to the receptor. This prevents receptor activation and subsequently inhibits downstream signaling pathways including RAS-RAF-MEK-ERK, PI3K-AKT-mTOR, and JAK-STAT, resulting in impaired cell proliferation and reduced cell survival.
Reference(s):
1. Foon KA et al. (2004). Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys.
2. Yang XD et al. (2001). Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol.
3. Wu M et al. (2008). Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clin Ther.